Slide 1: 2026 2Q Earnings Release
CELL BIOTECH Probiotics & Microbiome company 2026 2Q Earnings Release 2026. 08. As a note, it is suggested to use this material only as a reference, as it contains information and data that are subject to changes wi prior notice due to the external audit process, and may cause the actual results to
Slide 2: Revenue up 32.7% to KRW 15.8 billion, operating profit up 27.9%
CELL BIOTECH Revenue up 32.7% to KRW 15.8 billion, operating profit up 27.9% to KRW 1.6 billion Domestic revenue up 25.9%, overseas revenue up 39.7% Duolac brand sales up 3.7% to KRW 7.2 billion, OEM/ODM sales up 125% to KRW 7.1 billion, Raw material sales down -18% to KRW 1.5 billion (unit : KRW 10
Slide 3: Revenue trends
Revenue trends CELL BIOTECH Q2 revenue KRW 15.8 billion, yoy + 32.7%, qoq + 8.3% (unit : KRW mil) (unit : KRW mil) 18,000 56,000 16,000 54,000 atk 53,126 14,000 47-409; 52,000 12,000 | " 50,526 49,913 10,000 50,000 8,000 48,000 6,000 46,873 4,000 46,000 2,000 44,000 0 a 42,000 2021 ©2022,» «2023S 20
Slide 4: Quarterly profit / Full year profit
CELL BIOTECH Q2 operating profit KRW 1.6 billion, yoy +28% Net Profit KRW +3.6 billion, yoy +1,593% Quarterly profit Full year profit (unit : KRW mil) 4
Slide 5: Q2 revenue of Duolac brand, OEM/ODM and raw material
CELL BIOTECH Q2 revenue of Duolac brand +3.7% to 7.2 KRW bil., OEM/ODM +125.5% to 7.1 KRW bil., and raw material -17.9% to 1.5 KRW bil. (unit : KRW mil) 5
Slide 6: Business update
Business update CELL BIOTECH Microbiome R&D nee in global export for 13 consecutive 1) Microbiome First-in-Class anticancer pipeline ‘PP-P8’ 1) Cellbiotech's probiotics 'DUOLAC' ranked No. 1 clinical phase 1 IND submitted (Mar 5, 2021) : . P in the world for 13 consecutive years 2) Acquisition Europ
Slide 7: FDA GRAS World's Most Listed
CELL BIOTECH FDA GRAS World’s Most Listed 1) Cellbiotech "11 types of lactic acid bacteria 2) Cellbiotech, Probiotics Leading... Global Leap secured FDA GRAS certification... The World's Largest Holdings" https://www.hankyung.com/article/202402222016i https://www.dailypharm.com/Users/News/NewsVie w.
Slide 8: Now is the Era of K-Probiotics
CELL BIOTECH “Now is the Era of K-Probiotics” – Cellbiotech’s ‘Duolac’ Achieves No. 1 Market Share in Denmark, the Home Country 1) Surpassing Local Brand ‘Lactocare’ --- Assuming the Top Spot with a 46.6% Market Share https://n.news.naver.com/mnews/article/016/000261 4577?sid=101 8
Slide 9: Income statement and statement of financial position
CELL BIOTECH Income statement Statement of financial position (unit : KRW 100 mil., %) (unit : KRW 100 mil., %) 2025 2q 2026 2q 2025 .12 2026 2q Assets 1,366 1,449 Amount Ratio Amount Ratio Current Assets 1037 1,098 Revenue 119.1 100.0 158.1 100.0 Non current Assets 329 352 Gross profit 88.9 74.7 11